Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease by Helliwell, P, Coates, L, Fitzgerald, O, Nash, P, Soriano, E, Husni, M, Hsu, M, Kanik, K, Hendrikx, T, Wu, J, Kudlacz, E

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis by Helliwell, P, Coates, L, Fitzgerald, O, Nash, P, Soriano, E, Husni, M, Hsu, M, Kanik, K, Hendrikx, T, Wu, J, Kudlacz, E

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balanc... by Nash, P, Coates, L, Kivitz, A, Mease, P, Gladman, D, Covarrubias-Cobos, J, Fleishaker, D, Wang, C, Kudlacz, E, Menon, S, Fallon, L, Hendrikx, T, Kanik, K

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balanc... by Nash, P, Coates, L, Kivitz, A, Mease, P, Gladman, D, Covarrubias-Cobos, J, Fleishaker, D, Wang, C, Kudlacz, E, Menon, S, Fallon, L, Hendrikx, T, Kanik, K